(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Read the latest analysis on the stock here.

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...

HIV and tuberculosis (TB) treatment programs have always relied on clinical trials to understand whether treatment ...

Mean amyloid levels remained below 24.1 centiloids at 3 years for participants who completed donanemab treatment by 1 year. "These data, along with data from other donanemab studies, provide an ...

Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...